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Objective: The aim of this study was to evaluate the effect of stopping the agonist with the
ﬁrst follow up visit when the initial response was poor in cases undergoing intracytoplasmic
sperm injection, comparing this to the conventional continuation of the agonist.
Methodology: A prospective single blinded study was conducted on 50 infertile cases who
were planned to have intracytoplasmic sperm injection by long protocol in infertility unit of
El-Shatby Maternity University Hospital in the period between May 2011 and January 2013
and  these patients had poor response on day 6 of stimulation (serum estradiol (E2) less
than 100 pg/ml and 5 or less follicles developed). They were randomly allocated by closed
envelope method into two groups, (I) 30 patients to whom we  stopped the agonist and
continued stimulation and (II) 20 patients to whom we continued the agonist together with
stimulation.
Results: Group II had statistically higher days of stimulation than group I (p = 0.009). The
number of metaphase II oocytes did not show statistical signiﬁcant difference between the
two groups (p = 0.418). The mean of number embryos replaced were statistically higher in
group II than group I (p = 0.025). Pregnancy rate showed no statistical signiﬁcant differences
between the two studied groups (p = 0.466).
Conclusions: There was no difference between stopping the agonist or continuing it when
the  initial response was poor on ﬁrst follow up visit in cases undergoing intracytoplasmic
sperm injection.
Recommendations: Alternative measures should be looked for, to improve results of intracy-
toplasmic sperm injection when initial response is poor.©  2015 Sociedade Brasileira de Reproduc¸ão Humana. Published by Elsevier Editora Ltda.
All rights reserved.∗ Corresponding author.
E-mail: Ahmedsamyagwany@gmail.com (A.S. El-Agwany).
ttp://dx.doi.org/10.1016/j.recli.2015.11.006
413-2087/© 2015 Sociedade Brasileira de Reproduc¸ão Humana. Published by Elsevier Editora Ltda. All rights reserved.
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Protocolo  de  interrupc¸ão  não  planejada  de  agonista:  essa  medida  resgata
o  ciclo  de  injec¸ão intracitoplasmática  de  espermatozoide?  Estudo
randomizado  e  controlado
Palavras-chave:
Agonista do GnrH
IICE
Induc¸ão da ovulac¸ão
Reserva ovariana
r  e  s  u  m  o
Objetivo: O objetivo desse estudo foi avaliar o efeito da interrupc¸ão do agonista por ocasião
da  primeira consulta de seguimento, quando a resposta foi insatisfatória em casos tratados
com injec¸ão intracitoplasmática de espermatozoide (IICE), e comparar essa medida com a
continuac¸ão  convencional do agonista.
Metodologia: Um estudo prospectivo monocego foi realizado em 50 casos de infertilidade,
com planejamento de IICE por protocolo longo na Unidade de Infertilidade da Maternidade
do  Hospital Universitário El Shatby no período entre maio de 2011 e janeiro de 2013; essas
pacientes tiveram resposta insatisfatória no Dia 6 da estimulac¸ão (estradiol sérico [E2]
<  100 pg/ml e desenvolvimento de 5 ou menos folículos). As pacientes foram randomica-
mente designadas pelo método do envelope fechado para a formac¸ão de dois grupos: Grupo
I,  30 pacientes que tiveram interrompida a medicac¸ão com o agonista e continuaram com
a  estimulac¸ão, e Grupo II, 20 pacientes que continuaram com o agonista juntamente com a
estimulac¸ão.
Resultados: O Grupo II apresentou um número estatisticamente maior de dias de estimulac¸ão
versus Grupo I (p = 0,009). O número de ovócitos em metáfase II não exibiu diferenc¸a esta-
tisticamente signiﬁcativa entre os dois grupos (p = 0,418). O número médio de embriões
recuperados foi estatisticamente maior no Grupo II versus Grupo I (p = 0,025). O percentual
de  gestac¸ões não revelou diferenc¸as estatisticamente signiﬁcativas entre os dois grupos
estudados (p = 0,466).
Conclusões: Em casos tratados com IICE, não foi observada diferenc¸a entre a interrupc¸ão
do  agonista ou sua continuac¸ão, quando a resposta inicial foi insatisfatória na primeira
consulta de seguimento.
Recomendac¸ões: É preciso se pensar em medidas alternativas para melhorar os resultados
da  IICE, nos casos em que a resposta inicial não for satisfatória.
© 2015 Sociedade Brasileira de Reproduc¸ão Humana. Publicado por Elsevier Editora
Ltda. Todos os direitos reservados.Introduction
Low ovarian response to stimulation protocol in intracyto-
plasmic sperm injection (ICSI) is frustrating to physicians
and patients especially when the initial evaluation seems to
be fair. Regarding this emerging problem, different measures
usually taken trying to rescue the cycle and avoid cancelation.
It was estimated that about 9–18% of cycles result in this low
response with small number of follicles and low estradiol
level.1
The term “poor responder” has been used to determine
women who  require large doses of stimulation medications
and who make less than an optimal number of eggs. The def-
inition of low responders differs from center to other, but the
most used one is that less than four dominant follicles on day
of human chorionic gonadotropin (hCG) administration.2
The occurrence of low response to ovarian stimulation is
usually suspected in old age, although it could occur at any
age. Ovarian reserve is the main factor affecting response to
stimulation, it could be assessed by many  parameters as basal
follicle stimulating hormone (FSH), antral follicle count (AFC)
and anti-mullarian hormone (AMH). These parameters could
be normal, yet poor response happen. A lot of explanations
trying to answer the question of: why low ovarian reserve in
young patients.3The optimal protocol to deal with poor responders is con-
troversial, the same as the deﬁnition. There are many  trials,
including the use of higher doses of gonadotropins, differ-
ent doses of gonadotropin releasing hormone (GnRH) agonists,
adding estrogen or growth hormone, using combined oral con-
traceptive pills or the use of natural cycle.1,2
The long GnRH agonist protocol is the most widely used
and is the preferred for women planned to have ICSI. In poor
responders, release of this suppressive effect of GnRH may
change the response of the ovary by opening the ovarian
receptors. The concept of: GnRH agonist stop protocols developed
depending on this theory.4,5
These protocols are characterized by the use of some-
what low doses of GnRH agonists from the mid-luteal phase
of the cycle till the time of menses or soon later, this usu-
ally occurs in combination with high doses of gonadotropins.
Although GnRH agonist is stopped, it was found that the occur-
rence of unprogrammed luteinizing hormone (LH) surge is still
low.4,5
Materials  and  methodsThe aim of the study was to compare the results of ICSI in cases
of poor response on day 6 stimulation of long protocol between
patients who stopped the agonist and those who  continued it.
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Table 1 – Demographic and clinical data of the two studied groups.
Group I (30 women) Group II (20 women) p
Age
Mean ± SD 32.30 ± 5.86 32.8 ± 4.48 0.37
Type of infertility
Primary 22 (73.3%) 15 (75.0%) 0.473
Secondary 8 (26.7%) 5 (25.0%)
Duration of infertility
Mean ± SD 6.43 ± 3.27 6.5 ± 3.12 0.471
Indication
Tubal factor 9 (30.0%) 3 (15.0%) 0.221
Male factor 16  (53.3%) 13 (65.0%)
Uterine factor 4 (13.3%) 2 (10.0%)
Ovarian factor 1 (3.3%) 2 (10.0%)
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To reach this aim, this randomized controlled single
linded study was conducted on 50 infertile cases who were
lanned to have ICSI by long agonist protocol in infertility
nit of El-Shatby Maternity University Hospital in the period
etween May 2011 and January 2013.
These patients had poor response on D6 of stimulation
serum estradiol (E2) less than 100 pg/ml and 5 or less follicles
eveloped) and were randomly allocated by closed envelope
ethod into two groups: Group I: 30 patients to whom we
topped the agonist and continued stimulation. Group II: 20
atients to whom we continued the agonist together with
timulation.
All patients were assessed by basal FSH and AFC and
hey were within normal range beside the routine assessment
f infertile couple (transvaginal ultrasound, HSG and semen
nalysis) and they were candidates for ICSI.
The protocol used was the long agonist protocol in which:
a) pituitary desensitization was performed by the use of
onadotropin releasing hormone (GnRh) agonist (decapeptyl
.1 mg,  Ferring) in a daily subcutaneous dose started on cycle
ay 21. On second day of menses, pituitary downregulat-
on was assured and the dose was reduced to 0.05 mg  and
ontinued until day 6 of stimulation. (b) Ovarian stimula-
ion with urinary human menopausal gonadotropin (u-hMG)
Merional , IBSA) 75 IU and urinary follicle stimulating hor-
one (u-FSH) (Fostimon , IBSA) 75 IU. The standard initial
ose was 300 IU started from the third day of the cycle.
c) First assessment of ovarian response to stimulation is
one on D6 (after 5 days of stimulation), those who have E2
ess than 100 pg/ml and 5 or less follicles developed were
nrolled in the study and were randomly allocated into two
roups: Group I: 30 patients to whom we stopped the ago-
ist and continued stimulation. Group II: 20 patients to whom
e continued the agonist together with stimulation. And for
ll patients we  increased the dose of stimulation to 450 IU.
d) Follow up of ovulation was done every other day by estimat-
ng E2 and transvaginal ultrasound and the dose of stimulation
as adjusted till the criteria for administration of hCG waseached. (e) Ovulation was induced when there were 2 or
ore follicles greater than 18 mm in diameter by administra-
ion of hCG (Choriomon , IBSA) 10,000 IU subcutaneous (s.c.)
r intramuscular (i.m.) injection. Ovum pick up was done 35 hafter hCG administration guided by transvaginal ultrasound.
Embryo transfer was done on D3 under ultrasound guidance,
and was considered statistically signiﬁcant. All analyses were
performed using SPSS for Windows, version 18.0.
Results
Data  collection
Orientation and ofﬁcial approval from relevant authorities:
collaborative agreement.
In order to enable the researcher to conduct the study, the
necessary permissions to conduct the study were obtained.
Ethical consideration: The conﬁdentiality of collected data
was stressed and a written informal consent was taken from
all women.
Data  analysis
The chi-square (2) test was used to analyze categorical vari-
ables which were expressed as percentage values. Continuous
variables were reported as mean value and standard devi-
ation (SD) and analyzed using the t-test. The continuous
variables were also reported as median and analyzed using
Mann–Whitney test. A p-value was found to be <0.05.
Demographic  data
Demographic data and clinical data of the two studied groups
were presented in Table 1. It demonstrated that: the mean
age was 32.30 ± 5.86 and 321.8 ± 4.48 for groups I and II,
respectively; there were no statistical signiﬁcant differences
between the two studied groups regarding age (p = 0.37). Pri-
mary  infertility was 22 (73.3%) and 15 (75.0%), and secondary
infertility was 8 (26.7%) and 5 (25.0%) for groups I and II,
respectively; there were no statistical signiﬁcant differences
between the two studied groups regarding type of infertility
(p = 0.473). The mean of duration of infertility was 6.43 ± 3.27
and 6.5 ± 3.12 for groups I and II, respectively; there were
no statistical signiﬁcant differences between the two studied
groups (p = 0.471).
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Table 2 – Laboratory and maternal ﬁndings in the two studied groups.
Group I (30 women) Group II (20 women) p
D3 FSH 7.56 ± 1.66 7.04 ± 1.32 0.119
AFC 6.93 ± 2.16 9.30 ± 1.78 0.0001
D6 E2 70.97 ± 14.67 67.15 ± 20.70 0.224
D6 response 4.20 ± 0.71 4.00 ± 0.92 0.196
Days of stimulation 11.73 ± 0.98 12.55 ± 1.39 0.009a
Final E2 708.30 ± 195.37 863.60 ± 178.17 0.003a
Number of oocytes 4.77 ± 1.55 5.00 ± 1.59 0.304
Metaphase II oocytes 4.00 ± 1.60 4.10 ± 1.77 0.418
Number of embryo(s) 2.00 ± 1.44 2.65 ± 1.39 0.059
Number of embryo(s) transferred 1.87 ± 1.33 2.65 ± 1.39 0.025aFSH, follicle stimulating hormone; AFC, antral follicle count.
a Statistically signiﬁcant difference.
Laboratory  and  maternal  ﬁndings
Laboratory and maternal ﬁndings in the two studied groups
were presented in Table 2. It illustrated that: the mean of
D3 FSH was 7.56 ± 1.66 and 7.04 ± 1.32 for groups I and II
respectively; there were no statistical signiﬁcant differences
(p = 0.119).
The mean of AFC was 6.93 ± 2.16 and 9.30 ± 1.78 for groups
I and II, respectively; group II has values statistically higher
than group I (p = 0.0001). The mean of D6 E2 was 70.97 ± 14.67
and 67.15 ± 20.70 for groups I and II, respectively; there were
no statistical signiﬁcant differences (p = 0.224). The mean of
D6 response was 4.20 ± 0.71 and 4.00 ± 0.92 for groups I and II,
respectively; there were no statistical signiﬁcant differences
(p = 0.196). The mean of days of stimulation was 11.73 ± 0.98
and 12.55 ± 1.39 for groups I and II, respectively; group II has
values statistically higher than group I (p = 0.009). The mean
of ﬁnal E2 was 708.30 ± 195.37 and 863.60 ± 178.17 for groups
I and II, respectively; group II has values statistically higher
than group I (p = 0.003). The mean of number of oocytes was
4.77 ± 1.55 and 5.00 ± 1.59 for groups I and II, respectively; there
were no statistical signiﬁcant differences (p = 0.304). The mean
of metaphase II was 4.0 ± 1.60 and 4.10 ± 1.77 for groups I and
II, respectively; there were no statistical signiﬁcant differences
(p = 0.418). The mean of number of embryo was 2.0 ± 1.44 and
2.65 ± 1.39 for groups I and II, respectively; there were no sta-
tistical signiﬁcant differences (p = 0.059). The mean of number
of embryo replaced was 1.87 ± 1.33 and 2.65 ± 1.39 for groups
I and II, respectively; group II has values statistically higher
than group I (p = 0.025).
Pregnancy  rateTable 3 shows pregnancy rate in the two studied groups. It
demonstrated that pregnancy rate was 23.3% and 20.0% for
Table 3 – Pregnancy rate in the two  studied groups.
Group I (30 women) Group II (20 women)
No. of pregnancy 7 4
Pregnancy rate (%) 23.3 20.0
p 0.466groups I and II, respectively; there were no statistical signiﬁ-
cant differences between the two studied groups (p = 0.466).
Discussion
The results of our study showed that cessation of agonist on
D6 of stimulation when there is poor response does not differ
from continuation of the agonist as regard ICSI outcomes.
The value of agonist is to prevent premature LH surge and
thus prevent cycle cancelation, however, this may need higher
doses of gonadotropins.6
Although many  studies used early discontinuation of the
agonist, the incidence of premature LH surge was very low;  in
spite of this, the results are still contradictory.
The possible mechanism of action of agonist-stop protocol
is the reduced effect of the GnRH agonists on their ovarian
receptors and this leads to reduced ovarian suppression and
so increase ovarian response.4,5
Another possible mechanism is that GnRH agonists
decrease follicular blood ﬂow as proved by some studies and
stop of the agonist restores follicular blood ﬂow with no effect
on pituitary suppression and this helps to recruit more  follicles
and gives better ICSI outcomes.7–10
There are a lot of studies published about early cessa-
tion of agonist and the results differ, only two  of these
studies were prospective randomized controlled trials and
showed no statistically signiﬁcant difference in pregnancy
rates. Other studies were prospective trials with historical
controls or retrospective demonstrated improved pregnancy
outcome.
One prospective randomized, controlled trial involving
78 cycles, a “stop agonist” regimen was compared with
a standard long luteal protocol. GnRH agonist (buserelin
1 mg/day intranasally (i.n.) or triptorelin 0.1 mg/day, s.c.) was
started day 21 of the preceding cycle and stopped with
pituitary suppression and start of stimulation. Ovarian stimu-
lation with a dose of 225–375 IU/day hMG or puriﬁed FSH. The
results showed no improvement because the mean number of
the retrieved oocytes did not change and the pregnancy rate
11did not show signiﬁcant difference.
Another prospective, randomized, controlled trial com-
pared “stop” versus “non-stop” protocol of GnRH agonist,
together with high doses of gonadotropins. Leuprolide
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1 mg,  s.c.) was used from day 21 of the cycle and stopped
n the day of menses, followed by stimulation of ovulation
y a dose of 375–450 IU hMG  and/or puriﬁed FSH daily. The
esults of this study showed a signiﬁcantly higher number of
etrieved oocytes (8.7 versus 5.3 per cycle, p = 0.027) and higher
umber of mature oocytes, but there were similar fertiliza-
ion and cleavage rates as well as similar numbers of embryos
ransferred. There was no signiﬁcant difference in either can-
elation rate (5.7% versus 2.8%) or pregnancy rate (18.7% versus
4.3%).12
The other studies did not show the same results, they
ere prospective trials but used historical controls. One of
hem studied 224 cycles, in these cycles a low-dose mid-luteal
nRH agonist (leuprolide 0.5 mg,  s.c.) was given and stopped
ith the onset of menses and this was named by the authors
s the “stop-Lupron protocol”. Ovulation induction was done
y a dose of 450–600 IU of puriﬁed FSH or hMG (i.m.) daily.
he dose of gonadotropins was decreased 2 days prior
o hCG administration, The results of this study showed
ow cancelation rate (12.5%), high number of retrieved
ocytes (11.1), and higher clinical pregnancy rate per transfer
32%).13
A non-randomized prospective study used 52 cycles and
dministered 0.5 mg  leuprolide s.c. from day 21 to the next
ycle day 2 and stopped leuprolide. Ovulation was induced
ith a dose of 300–450 IU/day hMG  and puriﬁed FSH. The
esults of this study showed that there were a good response
o stimulation (mean 7.5 oocytes per cycle) as well as better
regnancy rates (20.5% per embryo transfer).14
Another prospective study with historical controls used
2 cycles and administered 0.5 mg leuprolide s.c. from day
1 to the next cycle day 2 and stopped leuprolide. Ovu-
ation was induced with a dose of 450–600 IU/day hMG
nd puriﬁed FSH. The results of this study showed that
here were high pregnancy rates (33.3%) and low cancelation
ates (31.6%).15
Another prospective study with historical controls which
nvolved 36 poor responders and used nafarelin (0.6 mg/day)
tarted in the mid-luteal phase and stooped on day 5 of ovarian
timulation. This protocol stopped the agonist late and this is
imilar to our protocol but this was planned as these patients
ere diagnosed as poor responders from the start. Ovulation
as induced with a dose of 300 IU/day hMG. The results of
his study showed increase in the number of retrieved oocytes
y 28%, decrease in cancelation rates (to 8.3%) and increase
regnancy rates (to 19.4%).16
In another prospective study with historical controls, and
sing also nafarelin (0.6 mg/day) started in the mid-luteal
hase but discontinued on day 1 of the next cycle and included
9 poor responders. Ovulation was induced with a dose of
00 IU/day hMG.  The results of this study showed increase
n the number of retrieved oocytes and the pregnancy rates
10.7% versus 2.8%).17
onclusionshere was no difference between stopping the agonist or con-
inuing it when the initial response was poor on ﬁrst follow up
isit in cases undergoing ICSI.
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Recommendations
Larger multicentric study is needed to evaluate this unplanned
agonist stop protocol.
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